POST-TEST

Up for Debate: Oncology Investigators Provide Their Take on Current Controversies in Patient Care

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING. 1. The Phase III ECHELON-1 trial 4. Results of the ANDROMEDA study, comparing (A) with which evaluated the addition of daratu- doxorubicin/vinblastine/dacarbazine mumab to CyBorD (cyclophosphamide, (AVD) to bleomycin with AVD (ABVD) for and ) for patients with previously untreated Stage patients with light chain amyloidosis, III or IV classical Hodgkin lymphoma included which of the following demonstrated which of the following outcomes? progression-free survival (PFS) outcomes a. The addition of daratumumab did at 5 years of follow-up? not improve complete hematologic a. No significant improvement with response rate A + AVD compared to ABVD b. The addition of daratumumab b. Significant improvement with improved the complete hematologic A + AVD compared to ABVD response rate c. The complete hematologic response 2. Results of the Phase III ELEVATE-RR rate was similar with and without head-to-head trial evaluating acalabru- the addition of daratumumab tinib versus for patients with previously treated chronic lymphocytic 5. The monarchE study evaluating adjuvant leukemia included which of the following abemaciclib in combination with outcomes in terms of the incidence of endocrine therapy versus endocrine atrial fibrillation (any grade)? therapy alone for patients with hormone a. A higher rate with receptor (HR)-positive, HER2-negative, b. A higher rate with ibrutinib node-positive high-risk early breast c. Similar rates with acalabrutinib cancer demonstrated which of the and ibrutinib following clinical outcomes on the abemaciclib arm? 3. The Phase III MAIA trial comparing a. Improvement in invasive disease- daratumumab, and free survival (IDFS) dexamethasone (D-Rd) to lenalidomide b. No improvement in IDFS and dexamethasone (Rd) for patients with newly diagnosed 6. Results of the RxPONDER trial, which ineligible for high-dose chemotherapy evaluated the addition of chemotherapy and transplant reported which of the to endocrine therapy for HR-positive, following PFS outcomes? HER2-negative breast cancer, included a. Improvement on the D-Rd study which of the following IDFS outcomes arm among women with a Recurrence Score® b. No significant difference between of 0 to 25 and 1 to 3 positive nodes? the arms a. Postmenopausal but not premeno- pausal women benefitted signifi- cantly from adjuvant chemotherapy b. Premenopausal but not postmeno- pausal women benefitted signifi- cantly from adjuvant chemotherapy c. Both premenopausal and postmenopausal women benefitted significantly from adjuvant chemo- therapy

QIDs 3405, 3406 POST-TEST

Up for Debate: Oncology Investigators Provide Their Take on Current Controversies in Patient Care

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

7. Which of the following drug types best 9. Which of the following antiandrogen describes ? agents has been associated with the a. EGFR tyrosine kinase inhibitor (TKI) lowest rate of fatigue among men with b. RET inhibitor prostate cancer? c. NTRK/ ROS1 TKI a. Apalutamide b. Enzalutamide 8. Which of the following outcomes was c. Darolutamide reported from the Phase III ADAURA trial evaluating as adjuvant 10. Which of the following drug types best therapy for patients with Stage IB to IIIA describes ? non-small cell lung cancer (NSCLC) with a. Antibody-drug conjugate EGFR mutations? b. Immune checkpoint inhibitor a. Significant benefit with osimertinib c. PI3 kinase inhibitor compared to placebo for patients with Stage IB to IIIA NSCLC b. Significant benefit with osimertinib compared to placebo for patients with Stage II and IIIA NSCLC but not for patients with Stage IB disease c. No benefit with osimertinib compared to placebo in any patient subgroup

QIDs 3405, 3406